Avadel Pharmaceuticals plc (AVDL)'s LUMRYZ Sales Surge 64% in Breakout Quarter

We recently compiled a list of the 11 Best Pharma Stocks to Invest in for the Long Term. Avadel Pharmaceuticals plc stands among them.

Avadel Pharmaceuticals plc (NASDAQ:AVDL), a Dublin-based biopharmaceutical company, is gaining attention in the sleep medicine space with its flagship product LUMRYZ™, the first and only once-at-bedtime oxybate therapy approved for narcolepsy patients with cataplexy or excessive daytime sleepiness.

The company’s growth has accelerated in 2025, fueled by the rapid adoption of LUMRYZ™. In its most recent quarter, Avadel Pharmaceuticals plc (NASDAQ:AVDL) reported a 64% year-over-year sales increase, reflecting strong demand from both patients and providers. August earnings further exceeded analyst expectations, strengthening optimism that LUMRYZ™ could become the standard of care in narcolepsy management.

Clinical development remains a priority, with ongoing Phase 3 trials supporting the product’s safety and efficacy profile. Success in these studies could lead to label expansions and broader patient access in the near future. Avadel Pharmaceuticals plc (NASDAQ:AVDL) is also investing in new clinical programs that may extend LUMRYZ’s use beyond narcolepsy to other central nervous system disorders, signaling a long-term strategy to diversify its portfolio.

While we acknowledge the potential of AVDL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.